In Focus

  • 10 Januar 2020 - Countries release genetic sequences of newly discovered coronavirus

    GISAID, The Chinese Center for Disease Control and Prevention, Chinese Academy of Science, Chinese Academy of Medical Science, EpiFlu Database
    TEM image of the hCoV-19 courtesy: IVDC, Chinese Center for Disease Control & Prevention

    Countries around the globe share an increasing number of hCoV-19 genome sequences

    Laboratories around the world are generating in an unprecedented manner, more and more genome sequences and related clinical and epidemiological data associated with the newly emerging coronavirus (hCoV-19) rapidly made available via GISAID. The pandemic virus was first identified in late December 2019 in Hubei Province, where patients were suffering from respiratory illnesses such as pneumonia. Since then, hCoV-19 is detected across the globe.

    The genome sequences of hCoV-19 are crucial to design and evaluate diagnostic tests, to track and trace the ongoing outbreak and to identify potential intervention options.

  • 28 February 2020 VCM Northern Hemisphere 2020-2021

    Recommended composition of influenza virus vaccines for use in the 2020-2021 Northern Hemisphere Influenza Season announced

    (Geneva, Switzerland) An advisory group of experts taking part in a meeting organized by the WHO Global Influenza Programme between 24-27 February 2020 analyzed influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS), and issued on 28 February 2020, recommendations on the composition of the influenza vaccines for the following influenza season.

    These recommendations are used by the national vaccine regulatory agencies and the pharmaceutical companies to develop, produce and license influenza vaccines.

    read more:

  • CBD Study finds GISAID might provide useful lessons and insight to ABS discussion

    CBD Study finds 'GISAID might provide useful lessons and insight to ABS discussions'

    A peer-reviewed fact-finding and scoping study on digital sequence information on genetic resources in the context of the Convention on Biological Diversity and the Nagoya Protocol, highlights key advantages of GISAID’s sharing mechanism and a fair and equitable benefit-sharing resulting from access to data.

    With the core principals of timely international sharing of health data for protecting populations against lethal infectious disease outbreaks and adherence to scientific etiquette of acknowledgement of the source of data has resulted in global trust and confidence in GISAID. 

    > download the fact-finding & scoping study

  • 19 May 2017 G20 Health Ministers

    G20 Health Ministers recognize the importance of GISAID in regard to virus data sharing

    At the invitation of Germany, the first meeting of Health Ministers of the Group of Twenty leading industrialized and emerging economies (G20) took place in Berlin between 19-20 May 2017.

    Under the banner of “Together Today for a Healthy Tomorrow – Joint Commitment for Shaping Global Health”, the two-day meeting focused on combating global health hazards. In their Berlin Declaration, the G20 Health Ministers recognize the importance of the Global Initiative on Sharing All Influenza Data (GISAID).

    > read more
    > The Berlin Declaration of the G20 Health Ministers (2017)

Public-Private Partnerships of the GISAID Initiative

The GISAID Initiative, originally known as a Global Initiative on Sharing All Influenza Data, involves public-private-partnerships between the Initiative's administrative arm Freunde of GISAID e.V., a registered non-profit association, and governments of the Federal Republic of Germany, the official host of the GISAID platform, Singapore and the United States of America, with support from private and corporate philanthropy.